C
CTKB icon

Covestor’s Cytek Biosciences CTKB Stock Holding History

Covestor’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
71
+50
+238% +$213 ﹤0.01% 2532
2026
Q1 		$0 Hold
21
– – ﹤0.01% 2334
2025
Q4 		$0 Hold
21
– – ﹤0.01% 2327
2025
Q3 		$0 Hold
21
– – ﹤0.01% 2349
2025
Q2 		$0 Buy
21
+11
+110% +$37 ﹤0.01% 2285
2025
Q1 		$0 Hold
10
– – ﹤0.01% 2300
2024
Q4 		$0 Sell
10
-15
-60% -$89 ﹤0.01% 2306
2024
Q3 		$0 Buy
25
+15
+150% +$85 ﹤0.01% 2292
2024
Q2 		$0 Hold
10
– – ﹤0.01% 2306
2024
Q1 		$0 Sell
10
-22
-69% -$174 ﹤0.01% 2306
2023
Q4 		$0 Buy
32
+20
+167% +$126 ﹤0.01% 2216
2023
Q3 		$0 Sell
12
-21
-64% -$168 ﹤0.01% 2193
2023
Q2 		$0 Buy
33
+19
+136% +$170 ﹤0.01% 2205
2023
Q1 		$0 Hold
14
– – ﹤0.01% 2101
2022
Q4 		$0 Sell
14
-1
-7% -$13 ﹤0.01% 2135
2022
Q3 		$0 Sell
15
-3
-17% -$39 ﹤0.01% 2076
2022
Q2 		$0 Sell
18
-6
-25% -$60 ﹤0.01% 1985
2022
Q1 		$0 Buy
+24
New +$324 ﹤0.01% 2159

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Covestor's CTKB Position: Q2 2026 in Review

Covestor increased its Cytek Biosciences (CTKB) stake by 238% in Q2 2026, buying an estimated $213 and bringing the position to 71 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

Covestor first reported a position in CTKB in Q1 2022 and has held it in 18 quarters since. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Covestor held 71 shares of Cytek Biosciences worth $0 as of Q2 2026.
  • Covestor bought 50 Cytek Biosciences shares in Q2 2026, an estimated $213.
  • Cytek Biosciences made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2532 holding.
  • Covestor first reported a position in Cytek Biosciences in Q1 2022 and has held it in 18 quarters since.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.